## SYK: Stryker Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.8% below STRENGTH zone (3.0-6.0%); PEG 1.86 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($357.92)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Scotia Capital Inc. Grows Stake in Stryker Corporation $SYK**
- Source: MarketBeat | 20251129T124727 | Somewhat-Bullish | Relevance: 99%
- Scotia Capital Inc. increased its stake in Stryker Corporation (NYSE:SYK) by 6.1% in Q2 2025, now holding 105,346 shares valued at $41.68 million. The medical technology company reported strong Q2 earnings, beating expectations, and saw significant insider selling alongside a "Moderate Buy" analyst consensus. Institutional investors own 77.09% of Stryker's stock, with analysts maintaining a consensus target price of $434.37 despite recent insider sales.

**2. Stryker Corporation $SYK Shares Bought by Vinva Investment Management Ltd**
- Source: MarketBeat | 20251129T115426 | Somewhat-Bullish | Relevance: 99%
- Vinva Investment Management Ltd increased its stake in Stryker Corporation by 15.3%, owning 20,871 shares valued at $8.21 million. This comes despite recent insider selling, with institutional investors holding 77.09% of the stock. Stryker also reported beating quarterly earnings estimates and provided positive FY2025 EPS guidance, earning a "Moderate Buy" consensus rating from analysts.

**3. Boston Family Office LLC Purchases 1,882 Shares of Stryker Corporation $SYK**
- Source: MarketBeat | 20251201T083128 | Somewhat-Bullish | Relevance: 98%
- Boston Family Office LLC increased its stake in Stryker Corporation by 2.9% in Q2, acquiring 1,882 shares, bringing its total to 66,391 shares valued at $26,266,000. Other major institutions like Vanguard, Price T. Rowe, Geode, and Norges Bank also increased their holdings, while corporate insiders sold a significant number of shares. Stryker recently exceeded quarterly EPS estimates with strong revenue growth and provided optimistic FY2025 EPS guidance, leading analysts to rate the stock as a "Moderate Buy."

**4. Railway Pension Investments Ltd Cuts Position in Stryker Corporation $SYK**
- Source: MarketBeat | 20251201T133834 | Somewhat-Bullish | Relevance: 98%
- Railway Pension Investments Ltd reduced its stake in Stryker Corporation by 4.7% in Q2, selling 1,900 shares and ending with 38,600 shares valued at $15.27 million. Institutional ownership of Stryker stands at 77.09%, while insiders sold a total of 522,118 shares valued at approximately $185.38 million in the last quarter. Analysts maintain a "Moderate Buy" rating with an average price target of $434.37, following strong Q3 results and positive FY2025 guidance.

**5. Groupama Asset Managment Buys 3,748 Shares of Stryker Corporation $SYK**
- Source: MarketBeat | 20251130T113908 | Somewhat-Bullish | Relevance: 98%
- Groupama Asset Management significantly increased its stake in Stryker Corporation in Q2 2025, purchasing 3,748 additional shares, bringing their total holdings to 5,593 shares valued at approximately $2.20 million. Wall Street analysts maintain a "Moderate Buy" rating for Stryker with an average target price of $434.37. The article also details recent insider selling and other institutional investor activities in Stryker stock.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-14 | Truist Securiti | $400 | $392 | +2% |
| 2025-11-14 | Wells Fargo | $456 | $452 | +1% |
| 2025-11-14 | Needham | $448 | $448 | 0% |
| 2025-11-14 | BTIG | $410 | $410 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-14 | Truist Securiti | main | Hold |
| 2025-11-14 | Wells Fargo | main | Overweight |
| 2025-11-14 | Needham | reit | Buy |
| 2025-11-14 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($34.68M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (+0.8%)
- Blackrock Inc.: 7.0% (+0.4%)
- JPMORGAN CHASE & CO: 6.2% (+95.3%)
- Greenleaf Trust: 4.3% (-0.3%)
- State Street Corpora: 3.9% (-0.1%)

### Key Risks

1. Heavy insider selling: $35M sold (6 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.86 elevated, pricing in significant growth expectations. Forward P/E 24.9x stretched relative to 10% growth. Balance sheet: $1.4B free cash flow. Insider selling cluster ($34.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $135.3B |
| Beta | 0.90 |
| 52W Range | $329.16 - $406.19 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.86 |
| Forward P/E | 24.9 |
| Current P/E | 27.5 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 0.9% to -0.8% (-1.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.8pp (needs >3.0% for momentum thesis). Below SMA200 (0.99x), long-term trend not supportive. MACD histogram positive (1.60), confirming momentum. RSI neutral at 54.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.82% (CS: 47) | Neutral |
| RSI_14 | 54.3 | Neutral |
| MACD Histogram | 1.60 | Bullish |
| vs SMA20 | 1.022x | Above |
| vs SMA50 | 1.009x | Above |
| vs SMA200 | 0.986x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $372.32
- **Stop Loss:** $357.92 (3.9% risk)
- **Target:** $386.72 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 52
- **Position Value:** $19,360.64
- **Portfolio %:** 19.36%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-01-27 (Est: $4.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.13 | $3.19 | +1.9% |
| 2025Q2 | $3.07 | $3.13 | +1.9% |
| 2025Q1 | $2.73 | $2.84 | +4.0% |
| 2024Q4 | $3.87 | $4.01 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*